• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outcome Selection for Research Studies in Movement Disorders.

作者信息

Fox Susan H

机构信息

University of Toronto, Movement Disorder Clinic, Edmond J Safra Program in Parkinson Disease, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.

出版信息

Mov Disord Clin Pract. 2024 Dec;11 Suppl 3(Suppl 3):S26-S30. doi: 10.1002/mdc3.14087. Epub 2024 Jun 3.

DOI:10.1002/mdc3.14087
PMID:38828689
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11616202/
Abstract
摘要

相似文献

1
Outcome Selection for Research Studies in Movement Disorders.运动障碍研究中的研究结果选择
Mov Disord Clin Pract. 2024 Dec;11 Suppl 3(Suppl 3):S26-S30. doi: 10.1002/mdc3.14087. Epub 2024 Jun 3.
2
Interventions for disorders of eye movement in patients with stroke.中风患者眼球运动障碍的干预措施。
Cochrane Database Syst Rev. 2011 Oct 5(10):CD008389. doi: 10.1002/14651858.CD008389.pub2.
3
Seeking impact: Global perspectives on outcome measure selection for translational and clinical research for primary mitochondrial disorders.寻求影响：原发性线粒体疾病转化和临床研究中结局测量选择的全球观点。
J Inherit Metab Dis. 2021 Mar;44(2):343-357. doi: 10.1002/jimd.12320. Epub 2020 Oct 29.
4
Do clinical trials prepare to fail by failing to prepare? An examination of MS trials and recommendations for patient-reported outcome measure selection.临床试验是否因为准备不足而导致失败？对多发性硬化症试验的考察以及对患者报告结局测量选择的建议。
Mult Scler Relat Disord. 2023 Aug;76:104788. doi: 10.1016/j.msard.2023.104788. Epub 2023 Jun 7.
5
Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential.移动医疗技术在运动障碍临床试验中的应用：未充分利用的潜力。
Neurotherapeutics. 2020 Oct;17(4):1736-1746. doi: 10.1007/s13311-020-00901-x.
6
Non-pharmacological interventions for spatial neglect or inattention following stroke and other non-progressive brain injury.非药物干预治疗脑卒中及其他非进行性脑损伤后空间忽略或注意力不集中。
Cochrane Database Syst Rev. 2021 Jul 1;7(7):CD003586. doi: 10.1002/14651858.CD003586.pub4.
7
Measures of outcome for stimulant trials: ACTTION recommendations and research agenda.兴奋剂试验的结果测量：ACCTION建议与研究议程。
Drug Alcohol Depend. 2016 Jan 1;158:1-7. doi: 10.1016/j.drugalcdep.2015.11.004. Epub 2015 Nov 21.
8
Parent-reported outcome measures evaluating communication in individuals with rare neurodevelopmental disorders: A systematic review.家长报告的结局评估工具在评估罕见神经发育障碍个体的沟通能力中的应用：系统综述。
Int J Lang Commun Disord. 2024 Nov-Dec;59(6):2528-2553. doi: 10.1111/1460-6984.13100. Epub 2024 Aug 14.
9
Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) acute day hospital versus admission; (2) vocational rehabilitation; (3) day hospital versus outpatient care.针对重度精神障碍患者日间护理效果的系统评价：（1）急性日间医院与住院治疗对比；（2）职业康复；（3）日间医院与门诊护理对比。
Health Technol Assess. 2001;5(21):1-75. doi: 10.3310/hta5210.
10
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区，服用抗叶酸抗疟药物的人群中，叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.

本文引用的文献

1
Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial.西那卡塞治疗早期帕金森病的疗效：来自 2 期 SPARK 临床试验的生物标志物评估结果。
Neurology. 2024 Mar 12;102(5):e209137. doi: 10.1212/WNL.0000000000209137. Epub 2024 Feb 5.
2
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research.神经元α-突触核蛋白病的生物学定义：建立研究用综合分期系统。
Lancet Neurol. 2024 Feb;23(2):178-190. doi: 10.1016/S1474-4422(23)00405-2.
3
Digital Mobility Measures: A Window into Real-World Severity and Progression of Parkinson's Disease.
数字移动性测量：洞察帕金森病真实世界严重度和进展的窗口。
Mov Disord. 2024 Feb;39(2):328-338. doi: 10.1002/mds.29689. Epub 2023 Dec 27.
4
Trial of Botulinum Toxin for Isolated or Essential Head Tremor.肉毒杆菌毒素治疗孤立性或原发性头部震颤的试验。
N Engl J Med. 2023 Nov 9;389(19):1753-1765. doi: 10.1056/NEJMoa2304192.
5
Placebo and nocebo effects and mechanisms associated with pharmacological interventions: an umbrella review.与药物干预相关的安慰剂和反安慰剂效应及机制：伞式综述。
BMJ Open. 2023 Oct 17;13(10):e077243. doi: 10.1136/bmjopen-2023-077243.
6
Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative.帕金森病疾病修饰临床试验的结局指标：EJS ACT-PD 多臂多阶段试验倡议共识文件。
J Parkinsons Dis. 2023;13(6):1011-1033. doi: 10.3233/JPD-230051.
7
Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression.帕金森进展标志物倡议：一种基于里程碑的策略，用于监测帕金森病的进展。
J Parkinsons Dis. 2023;13(6):899-916. doi: 10.3233/JPD-223433.
8
Wearable movement-tracking data identify Parkinson's disease years before clinical diagnosis.可穿戴运动追踪数据可在临床诊断前数年识别帕金森病。
Nat Med. 2023 Aug;29(8):2048-2056. doi: 10.1038/s41591-023-02440-2. Epub 2023 Jul 3.
9
Defining Clinical Meaningfulness in Huntington's Disease.定义亨廷顿病的临床意义。
Mov Disord. 2023 Jun;38(6):1036-1043. doi: 10.1002/mds.29394. Epub 2023 May 5.
10
Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension.试验报告中结果报告指南：CONSORT-结果2022扩展版
JAMA. 2022 Dec 13;328(22):2252-2264. doi: 10.1001/jama.2022.21022.